DNA vaccines for malaria: the past, the present, & the future.

Doolan, D L; Hedstrom, R C; Wang, R; Sedegah, M; Scheller, L F; Hobart, P; Norman, J A; Hoffman, S L.
Artículo en Inglés | IMSEAR | ID: sea-21012

Documentos relacionados

  1. Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.
  2. DNA vaccines for malaria: the past, the present, & the future.
  3. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque.
  4. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
  5. The dog that did not bark: malaria vaccines without antibodies.
  6. A multilateral effort to develop DNA vaccines against falciparum malaria.
  7. Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.
  8. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
  9. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230.
  10. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.